EUDA Market Analysis
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 7.81
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- 4.96
- EV/EBITDA
- -25.90
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -34.8%
- Revenue growth YoY
- 78.9%
- Dividend yield
- —
- Beta
- 0.68
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About EUDA Health Holdings Limited
Company profileEUDA Health Holdings Limited is a forward-looking biopharmaceutical company focused on innovating treatments for rare diseases and addressing unmet medical needs. Leveraging advanced technologies, the firm is developing a robust clinical pipeline with a particular emphasis on supportive care and immune modulation. EUDA's strong commitment to research and development positions it favorably in the healthcare landscape, aiming to enhance patient outcomes and expand access to crucial therapies.
Classification
- Sector
- Real Estate
- Industry
- Real Estate Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer